News

PATH also announced that several global experts in vaccine development and introduction have joined PATH CVIA to advance these critical vaccine efforts. “We are excited to continue our

Alecensa has significantly decreased  the risk of disease deterioration or death (progression-free survival, PFS) by 85% compared against chemotherapy in patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small

Noctiva is a proprietary low-dose formulation of desmopressin acetate administered through a patent-protected intranasal delivery system. It is the first and only product approved by the U.S. Food

 Glioblastoma multiforme and anaplastic astrocytoma are the most common and most severe forms of non-metastatic brain cancer. According to the Central Brain Tumor Registry of the United States,

Keytruda has been approved as a monotherapy to treat locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy and adults who are not

The Company expects to enter the clinic in Q4 2017, pending the regulatory approval to conduct the clinical trial which is expected shortly. These indolent and rare hormone

The manufacturing license follows an inspection by the Spanish Medicines Agency (AEMPS), and provides production capacity for the potential initial European commercial roll out of Cx601, an investigational

The Swiss pharma major has reported positive topline results from the study, which assessed the safety and efficacy of oral once-daily fingolimod in children and adolescents (ages 10 to

“We are very excited to dose the first patient and initiate the Phase 2 trial of AG013 for oral mucositis, one of the most common and debilitating complications